{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T10:51:36Z","timestamp":1783075896802,"version":"3.54.6"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1097\/ftd.0000000000000051","type":"journal-article","created":{"date-parts":[[2014,2,21]],"date-time":"2014-02-21T10:30:44Z","timestamp":1392978644000},"page":"494-498","source":"Crossref","is-referenced-by-count":47,"title":["Lacosamide Serum Concentrations in Adult Patients With Epilepsy"],"prefix":"10.1097","volume":"36","author":[{"given":"Sofia","family":"Markoula","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rute","family":"Teotonio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neville","family":"Ratnaraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John S.","family":"Duncan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josemir W.","family":"Sander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip N.","family":"Patsalos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-11-20210129","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1517\/14656566.2012.667803","article-title":"Pharmacotherapy of the third-generation AEDs: lacosamide, retigabine and eslicarbazepine acetate.","volume":"13","author":"Patsalos","year":"2012","journal-title":"Expert Opin Pharmacother"},{"key":"R2-11-20210129","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1111\/j.1528-1167.2007.01188.x","article-title":". Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures.","volume":"48","author":"Ben-Menachem","year":"2007","journal-title":"Epilepsia"},{"key":"R3-11-20210129","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1517\/14656566.2010.488639","article-title":"Lacosamide: new adjunctive treatment option for partial-onset seizures.","volume":"11","author":"Chung","year":"2010","journal-title":"Expert Opin Pharmacother"},{"key":"R4-11-20210129","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1586\/ern.12.50","article-title":"Lacosamide for the treatment of partial-onset seizures.","volume":"12","author":"Biton","year":"2012","journal-title":"Expert Rev Neurother"},{"key":"R5-11-20210129","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.nurt.2006.10.002","article-title":". Lacosamide.","volume":"4","author":"Doty","year":"2007","journal-title":"Neurotherapeutics"},{"key":"R6-11-20210129","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eplepsyres.2006.10.008","article-title":". Progress report on new antiepileptic drugs: a summary of the eighth Eilat conference (Eilat VIII).","volume":"73","author":"Bialer","year":"2007","journal-title":"Epilepsy Res"},{"key":"R7-11-20210129","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1177\/0091270009347675","article-title":"No pharmacokinetic interaction between lacosamide and carbamazepine in healthy volunteers.","volume":"50","author":"Cawello","year":"2010","journal-title":"J Clin Pharmacol"},{"issue":"suppl 4","key":"R8-11-20210129","first-page":"200","article-title":". Low potential for drug-drug interaction of lacosamide.","volume":"47","author":"Thomas","year":"2006","journal-title":"Epilepsia"},{"key":"R9-11-20210129","first-page":"1595","article-title":"Absorption, disposition, metabolic fate and elimination of the anti-epileptic drug lacosamide in humans: mass balance following intravenous and oral administration.","volume":"11","author":"Cawello","year":"2010","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"R10-11-20210129","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eplepsyres.2004.07.010","article-title":". Progress report on new antiepileptic drugs: a summary of the seventh Eilat conference (Eilat VII).","volume":"61","author":"Bialer","year":"2004","journal-title":"Epilepsy Res"},{"key":"R11-11-20210129","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1046\/j.1528-1157.2002.13001.x","article-title":". The importance of drug interactions in epilepsy therapy.","volume":"43","author":"Patsalos","year":"2002","journal-title":"Epilepsia"},{"key":"R13-11-20210129","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1586\/ecp.12.10","article-title":"Methodologies used to identify and characterize interactions among antiepileptic drugs.","volume":"5","author":"Johannessen Landmark","year":"2012","journal-title":"Expert Rev Clin Pharmacol"},{"key":"R14-11-20210129","first-page":"1129","article-title":". Population pharmacokinetics of LCM in subjects with partial-onset seizures: results from two phase III trials.","volume":"48","author":"Nickel","year":"2008","journal-title":"J Clin Pharmacol"},{"key":"R15-11-20210129","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1177\/0091270011426875","article-title":"No pharmacokinetic interaction between lacosamide and valproic acid in healthy volunteers.","volume":"52","author":"Cawello","year":"2012","journal-title":"J Clin Pharmacol"},{"key":"R16-11-20210129","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1097\/FTD.0b013e318290eacc","article-title":". Lacosamide therapeutic monitoring in patients with epilepsy: effect of concomitant antiepileptic drugs.","volume":"35","author":"Contin","year":"2013","journal-title":"Ther Drug Monit"},{"key":"R17-11-20210129","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1111\/j.1528-1167.2009.02496.x","article-title":". Lacosamide as adjunctive therapy for partial-onset seizures: a randomized controlled trial.","volume":"51","author":"Chung","year":"2010","journal-title":"Epilepsia"},{"key":"R18-11-20210129","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1586\/14737175.9.1.33","article-title":". Lacosamide: pharmacology, mechanisms of action and pooled efficacy and safety data in partial-onset seizures.","volume":"9","author":"Beydoun","year":"2009","journal-title":"Expert Rev Neurother"},{"key":"R19-11-20210129","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1358\/dot.2008.44.1.1178468","article-title":"Lacosamide. An investigational drug for adjunctive treatment of partial-onset seizures.","volume":"44","author":"Ben-Menachem","year":"2008","journal-title":"Drugs Today (Barc)"},{"key":"R20-11-20210129","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/j.1528-1167.2008.01951.x","article-title":". Adjunctive lacosamide for partial-onset seizures: efficacy and safety results from a randomized controlled trial.","volume":"50","author":"Halasz","year":"2009","journal-title":"Epilepsia"},{"key":"R21-11-20210129","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1097\/FTD.0b013e3181dcc5fb","article-title":". A high-performance liquid chromatography assay to monitor the new antiepileptic drug lacosamide in patients with epilepsy.","volume":"32","author":"Greenaway","year":"2010","journal-title":"Ther Drug Monit"},{"key":"R22-11-20210129","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/00007691-200306000-00016","article-title":". Therapeutic drug monitoring of the newer antiepileptic drugs.","volume":"25","author":"Johannessen","year":"2003","journal-title":"Ther Drug Monit"},{"key":"R23-11-20210129","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1528-1167.2008.01561.x","article-title":". Antiepileptic drugsbest practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE commission on therapeutic strategies.","volume":"49","author":"Patsalos","year":"2008","journal-title":"Epilepsia"},{"key":"R24-11-20210129","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.3390\/ph3061909","article-title":"Therapeutic drug monitoring of the newer anti-epilepsy medications.","volume":"3","author":"Krasowski","year":"2010","journal-title":"Pharmaceuticals (Basel)"},{"key":"R25-11-20210129","first-page":"161","article-title":"Therapeutic drug monitoring of newer antiepileptic drugs.","volume":"35","author":"Brandt","year":"2011","journal-title":"J Lab Med"},{"key":"R26-11-20210129","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1097\/00007691-199712000-00003","article-title":". Lamotrigine plasma concentrations in children and adults: influence of age and associated therapy.","volume":"19","author":"Battino","year":"1997","journal-title":"Ther Drug Monit"},{"key":"R27-11-20210129","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1097\/00007691-200206000-00007","article-title":"Serum concentrations of topiramate in patients with epilepsy: influence of dose, age, and comedication.","volume":"24","author":"May","year":"2002","journal-title":"Ther Drug Monit"},{"key":"R28-11-20210129","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1097\/FTD.0b013e31815d0cd5","article-title":". Serum concentrations of pregabalin in patients with epilepsy: the influence of dose, age, and comedication.","volume":"29","author":"May","year":"2007","journal-title":"Ther Drug Monit"},{"key":"R29-11-20210129","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/01.ftd.0000155342.93489.fd","article-title":". 10-Hydroxycarbazepine serum concentration-to-oxcarbazepine dose ratio: influence of age and concomitant antiepileptic drugs.","volume":"27","author":"Armijo","year":"2005","journal-title":"Ther Drug Monit"},{"key":"R30-11-20210129","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1111\/j.1528-1167.2007.01043.x","article-title":". Effect of age and comedication on levetiracetam pharmacokinetics and tolerability.","volume":"48","author":"Hirsch","year":"2007","journal-title":"Epilepsia"},{"key":"R31-11-20210129","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1527-3458.2007.00001.x","article-title":". Lacosamide: a review of preclinical properties.","volume":"13","author":"Beyreuther","year":"2007","journal-title":"CNS Drug Rev"},{"key":"R32-11-20210129","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1111\/epi.12085","article-title":". Pharmacodynamic and pharmacokinetic evaluation of coadministration of lacosamide and an oral contraceptive (levonorgestrel plus ethinylestradiol) in healthy female volunteers.","volume":"54","author":"Cawello","year":"2013","journal-title":"Epilepsia"},{"key":"R33-11-20210129","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.eplepsyres.2011.03.019","article-title":". Fluctuation of lacosamide serum concentrations during the day and occurrence of adverse drug reactionsfirst clinical experience.","volume":"95","author":"Sattler","year":"2011","journal-title":"Epilepsy Res"},{"issue":"suppl 7","key":"R34-11-20210129","first-page":"31","article-title":". Pharmacokinetics of the new antiepileptic drug SPM 927 in human subjects with different age and gender.","volume":"45","author":"Schiltmeyer","year":"2004","journal-title":"Epilepsia"},{"key":"R35-11-20210129","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s40262-013-0067-4","article-title":"Clinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age: an update.","volume":"52","author":"Italiano","year":"2013","journal-title":"Clin Pharmacokinet"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000051","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:28:14Z","timestamp":1620952094000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201408000-00011"}},"subtitle":["The Influence of Gender, Age, Dose, and Concomitant Antiepileptic Drugs"],"short-title":[],"issued":{"date-parts":[[2014,8]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000051","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2014,8]]}}}